As HDAC, MEK, and BCL2 inhibitors have shown promising pre‐clinical efficacy against MLL‐rearranged ALL [15, 38, 39, 40], these drug classes are of particular interest. Here, BCL2 is linked to acute lymphoblastic leukemia.